Briefly, anti-inflammatory drugs take a central role in MM therapy and are applied to both standard therapy and maintenance therapy for MM patients, given the pivotal role of NF-κB and inflammation in MM progression. The gene discussed is NFKB1; the disease is Miyoshi myopathy.